Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New CV Outcomes Study May Mean Big Boost For Amgen's Repatha Market

Executive Summary

The addressable patient population in the US could increase by 4.5m if new trial is successful.

Advertisement

Related Content

Sanofi/Regeneron Cut Praluent List Price As PBMs Look To Maintain Rebate Status Quo
Amgen Drops Repatha List Price 60% To Cut Medicare Co-Pays And Boost Use
PCSK9 Inhibitor Labeling Parity Is Within Reach As Praluent And Repatha Strive To Make Commercial Case
Outcomes Claim May Help Amgen Make Case For PCSK9 Inhibitor Repatha
Medicines Company Gets Aggressive With Inclisiran Phase III Plans
Is Amgen's FOURIER Enough For Physicians, Payers To Expand Repatha Use?
PCSK9 Inhibitors' First Birthday Brings Sluggish Sales And More Bad Press

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel